VPT:CC - Single Ventricle Congenital Heart Disease Study Launches at Leading Academic Medical Center using Ventripoint's VMS+3.0 Whole-Heart Analysis System
(TheNewswire)
Toronto, Ontario – TheNewswire –June 2 9 , 2022 - VentripointDiagnostics Ltd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce acollaboration with Duke University School of Medicine in a new studythat analyzes single ventricle cardiac function in children. This willbe the first study to validate the VMS+3.0 in children with functionalsingle ventricles.
“The goal of non-invasive pediatric cardiac imagingis always to make the most accurate diagnosis, while simultaneouslydisturbing the child as little as possible” states Dr. Piers Barker,Pediatric Cardiologist at the Duke Pediatric and Congenital HeartCenter. “New 3-dimensional technologies could have the potentialto help us better achieve that goal for our patients with the mostcomplex congenital heart disease.”
Congenital heart disease represents the most commonsingle organ birth defect, with an incidence of approximately 1 in 100live births. Many of these children are born with critical congenitalheart disease, requiring cardiac surgery or other interventions beforetheir first birthday to survive. One of the most critical conditionsoccurs when children have only a functional single ventricle, in whichonly one of the two pumping chambers is developed. These childrenrequire the most intensive diagnostic and interventional care due tothe enormous complexity of how each heart forms, through infancy andinto adulthood.
“Ventripoint began to identify a means to improveheart diagnostics for children and especially for infants born with aheart abnormality,” stated Dr. George Adams, Executive-Chairman ofVentripoint. “We are delighted to partner with the leading pediatriccardiology group at Duke to verify the use of the VMS+3.0 in singleventricle patients.”
Children with functional single ventricles typicallyundergo a series of three staged surgeries in order to achieveadequate blood flow to both the body and the lungs. However,complications and a risk of heart failure accompany every stage, withthe risk becoming greater as children approach adulthood. Standardechocardiography assessments are difficult to apply to these patientsgiven how different the cardiac anatomy is as compared to a normalheart. Novel, 3-dimensional diagnostic tools like VMS+3.0 thereforeprovide a great opportunity to accurately assess heart function andenable proactive treatment prior to the development of heart failureor deterioration to the point of transplantation or death. Theresearch study will utilize the strengths of the Ventripoint systemwith the patient databases of the Duke Pediatric and Congenital HeartCenter and the Duke Cardiovascular Magnetic Resonance Center tovalidate the VMS+ for use in this patient population.
Funding for this study is generously provided by theTrawick Pediatric Cardiology Research Fund – Supporting SingleVentricle Research.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the resultof a decade of development and provides accurate volumetric cardiacmeasurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products andguides our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news releaseare made as of the date hereof and the Company undertakes noobligation to update publicly or revise any forward-looking statementsor information, whether as a result of new information, future eventsor otherwise, unless so required by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.